Company: CMND
Filing Date: 2025-12-05
Form Type: F-1/A
Source: 0001213900-25-118772
Chunk: 282

Company: Clearmind Medicine Inc.
Filing Date: 2025-12-05
Form: F-1/A
Chunk 282
---
:----|------------:|----------:|:--|
|                                    |     | October 31, |           |   |     | October 31, |           |   |     | October 31, |           |   |
|                                    |     |        2024 |           |   |     |        2023 |           |   |     |        2022 |           |   |
| Research and                       
 preclinical studies                |     |           $ |   747,026 |   |     |           $ | 1,159,147 |   |     |           $ | 2,380,942 |   |
| Salaries, regulatory, professional 
 and other expenses                 |     |             |   542,615 |   |     |             |   469,667 |   |     |             |   666,125 |   |
| Share-based compensation           
 (Notes 6, 10 and 11)               |     |             |   132,502 |   |     |             |    45,870 |   |     |             |   213,299 |   |
| Reimbursements (Note 6)            |     |             |   (50,319 | ) |     |             |  (141,409 | ) |     |             |  (194,205 | ) |
| Amortization                       
 of intangible assets               |     |             |    10,984 |   |     |             |    10,954 |   |     |             |    14,830 |   |
| Total research and development,    
 net                                |     |           $ | 1,382,808 |   |     |           $ | 1,544,229 |   |     |           $ | 3,080,991 |   |

| 19. | Subsequent 
 Events     |

| a. | During November 2024, the Company sold all the shares of Polyrizon, for total proceeds of $82,961. |

| b. | During the period between December 13, 2024 and December 26, 2024, April 2023 Warrants, September 2023 Warrants and January 2024 Warrants, were exercised into 310,388 common shares, for gross proceeds of $441,577. |

F-37 CLEARMIND MEDICINE INC. Condensed Interim Consolidated Financial Statements For